AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37452356 — intervention group
Group type: EXPERIMENTAL
Intervention: Unity prosthetic add-on suspension system
Number of subjects: 20
Study 37452374 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor-informed methylation-based MRD (timMRD)
Number of subjects: 195
Study 37452374 — intervention group
Group type: COMPARATOR
Intervention: Tumor-informed somatic mutation status
Number of subjects: 195
Study 37452403 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Nordic diet (HND)
Number of subjects: 42
Study 37452403 — intervention group
Group type: COMPARATOR
Intervention: Moderate carbohydrate-restricted diet (MCRD)
Number of subjects: 42
Study 37452428 — intervention group
Group type: EXPERIMENTAL
Intervention: Branched-chain amino acids (BCAA) intake
Number of subjects: 85
Study 37452428 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 85
Study 37452577 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation intervention
Number of subjects: 22
Study 37452640 — intervention group
Group type: EXPERIMENTAL
Intervention: MTA Angelus
Number of subjects: 137
Study 37452640 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Fill BC
Number of subjects: 137
Study 37452640 — intervention group
Group type: EXPERIMENTAL
Intervention: Both materials
Number of subjects: 137
Study 37452707 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra (100 mg subcutaneous within 8 hours of onset, followed by five 100 mg subcutaneous injections every 12 hours)
Number of subjects: 25
Study 37452707 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matched to anakinra treatment)
Number of subjects: 25
Study 37452734 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resolution magnetic resonance imaging (HR-MRI)
Number of subjects: 168
Study 37452805 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketone Ester (KE)
Number of subjects: 12
Study 37452849 — intervention group
Group type: EXPERIMENTAL
Intervention: SIBP04 (bevacizumab biosimilar) combined with carboplatin and paclitaxel
Number of subjects: 398
Study 37452882 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 synchronous, virtual CBSM group sessions immediately (n=41)
Number of subjects: 75
Study 37452882 — intervention group
Group type: COMPARATOR
Intervention: 10 synchronous, virtual CBSM group sessions after a 6-month waitlist (n=34)
Number of subjects: 75
Study 37452894 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended Knee Control
Number of subjects: 502
Study 37452894 — intervention group
Group type: EXPERIMENTAL
Intervention: Adductor strength programme
Number of subjects: 502
Study 37452894 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (self-chosen IPEP)
Number of subjects: 502
Study 37452894 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 502
Study 37452894 — intervention group
Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 502
Study 37452974 — intervention group
Group type: EXPERIMENTAL
Intervention: Desarda hernioplasty
Number of subjects: 110
Study 37452974 — intervention group
Group type: COMPARATOR
Intervention: Lichtenstein hernioplasty
Number of subjects: 110
Study 37453138 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 724
Study 37453138 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 724
Study 37453242 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-CNN
Number of subjects: 143
Study 37453242 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermatologists
Number of subjects: 143
Study 37453242 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented Intelligence
Number of subjects: 143
Study 37453242 — intervention group
Group type: EXPERIMENTAL
Intervention: 2D-CNN
Number of subjects: 143
Study 37453242 — intervention group
Group type: COMPARATOR
Intervention: Gold standard
Number of subjects: 143
Study 37453249 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal home care intervention
Number of subjects: 0
Study 37453249 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard home care)
Number of subjects: 0
Study 37453361 — intervention group
Group type: EXPERIMENTAL
Intervention: Third vaccine dose
Number of subjects: 356
Study 37453361 — intervention group
Group type: EXPERIMENTAL
Intervention: Fourth vaccine dose
Number of subjects: 356
Study 37453361 — intervention group
Group type: EXPERIMENTAL
Intervention: Three doses and infection
Number of subjects: 356
Study 37453361 — intervention group
Group type: EXPERIMENTAL
Intervention: Three and four vaccine doses
Number of subjects: 356
Study 37453361 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific primary immunodeficiencies and immunosuppressive medication
Number of subjects: 356
Study 37453361 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall study findings
Number of subjects: 356
Study 37453367 — intervention group
Group type: EXPERIMENTAL
Intervention: Onconum software platform for extracting and structuring information from electronic health records (EHRs) using machine learning and natural language processing techniques.
Number of subjects: 9599
Study 37453445 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-low tidal volume (ULTV) ventilation
Number of subjects: 215
Study 37453445 — intervention group
Group type: COMPARATOR
Intervention: Low tidal volume (LTV) ventilation
Number of subjects: 215
Study 37453536 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-FFR with a coarse-to-fine subpixel algorithm
Number of subjects: 316
Study 37453536 — intervention group
Group type: COMPARATOR
Intervention: CCTA >50% stenosis
Number of subjects: 316
Study 37453536 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-FFR
Number of subjects: 316
Study 37453536 — intervention group
Group type: COMPARATOR
Intervention: CCTA
Number of subjects: 316
Study 37453736 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 1969
Study 37453736 — intervention group
Group type: COMPARATOR
Intervention: QQ genotype
Number of subjects: 1969
Study 37453737 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept + Methotrexate (n = 310)
Number of subjects: 409
Study 37453737 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept monotherapy (n = 99)
Number of subjects: 409
Study 37453737 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept + Methotrexate
Number of subjects: 409
Study 37453737 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept monotherapy
Number of subjects: 409
Study 37453737 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept + Methotrexate and Abatacept monotherapy
Number of subjects: 409
Study 37453737 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 409
Study 37453737 — intervention group
Group type: COMPARATOR
Intervention: Baseline Methotrexate
Number of subjects: 409
Study 37453996 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic segmentation
Number of subjects: 31
Study 37453996 — intervention group
Group type: COMPARATOR
Intervention: Manual segmentation
Number of subjects: 31
Study 37453996 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of automatic vs manual segmentation
Number of subjects: 31
Study 37453996 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with hepatotoxicity
Number of subjects: 31
Study 37454014 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 months of preoperative endocrine therapy (pre-ET)
Number of subjects: 37
Study 37454148 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g of marine omega-3 FA per day (460 mg eicosapentanoic acid and 380 mg docosahexaenoic acid) and 2000 IU Vitamin D
Number of subjects: 0
Study 37454148 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 37454162 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectral multiphasic CT Angiography (mCTA)
Number of subjects: 31
Study 37454162 — intervention group
Group type: EXPERIMENTAL
Intervention: CT Angiography (mCTA)
Number of subjects: 31
Study 37454537 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorouracil and folinic acid with panitumumab (Pmab) as maintenance therapy
Number of subjects: 377
Study 37454537 — intervention group
Group type: COMPARATOR
Intervention: Fluorouracil and folinic acid without panitumumab (Pmab) as maintenance therapy
Number of subjects: 377
Study 37454728 — intervention group
Group type: EXPERIMENTAL
Intervention: CLARO+ intervention including overdose prevention, recognition and response training, lethal means safety counseling, and Caring Contacts.
Number of subjects: 0
Study 37454728 — intervention group
Group type: COMPARATOR
Intervention: CLARO intervention (baseline intervention without additional components).
Number of subjects: 0
Study 37454733 — intervention group
Group type: EXPERIMENTAL
Intervention: CHW+
Number of subjects: 31
Study 37454733 — intervention group
Group type: COMPARATOR
Intervention: TAU
Number of subjects: 31
Study 37454754 — intervention group
Group type: EXPERIMENTAL
Intervention: Centralized clinical support pathway intervention directed by population health coordinators
Number of subjects: 600
Study 37454762 — intervention group
Group type: EXPERIMENTAL
Intervention: High flow oxygen (HFO) > 6 l/minute
Number of subjects: 448
Study 37454762 — intervention group
Group type: COMPARATOR
Intervention: Low flow oxygen (LFO) ≤ 6 litres/minute
Number of subjects: 448
Study 37454762 — intervention group
Group type: COMPARATOR
Intervention: No supplemental oxygen (NSO)
Number of subjects: 448
Study 37454762 — intervention group
Group type: EXPERIMENTAL
Intervention: Remdesivir initiation ≥ 2 days after admission
Number of subjects: 448
Study 37454789 — intervention group
Group type: EXPERIMENTAL
Intervention: 38% silver diamine fluoride (SDF) solution
Number of subjects: 148
Study 37454789 — intervention group
Group type: COMPARATOR
Intervention: 5% potassium nitrate solution (control)
Number of subjects: 148
Study 37455151 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Number of subjects: 74
Study 37455151 — intervention group
Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 74
Study 37455214 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib and Gemcitabine (SG)
Number of subjects: 85
Study 37455214 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib alone (S)
Number of subjects: 85
Study 37455237 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-day AZLI (75 mg three times daily for 14 days)
Number of subjects: 149
Study 37455237 — intervention group
Group type: COMPARATOR
Intervention: 28-day AZLI (75 mg three times daily for 28 days)
Number of subjects: 149
Study 37455345 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive chemotherapy
Number of subjects: 38
Study 37455345 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic haematopoietic stem cell transplantation (allo-HSCT)
Number of subjects: 38
Study 37455355 — intervention group
Group type: EXPERIMENTAL
Intervention: QFR+/AMR+ group
Number of subjects: 942
Study 37455355 — intervention group
Group type: COMPARATOR
Intervention: QFR-/AMR- group
Number of subjects: 942
Study 37455355 — intervention group
Group type: EXPERIMENTAL
Intervention: CFV < 17.4 cm/s
Number of subjects: 942
Study 37455355 — intervention group
Group type: COMPARATOR
Intervention: CFV ≥ 17.4 cm/s
Number of subjects: 942
Study 37455404 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam nasal spray (Valtoco) as rescue therapy for seizure clusters
Number of subjects: 64
Study 37455496 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab (8 mg/kg i.v. on day 1 and 15, Q2W) plus TAS-102 (35 mg/m²)
Number of subjects: 0
Study 37455531 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with depressive symptoms (BDI ≥10) in CAD
Number of subjects: 587
Study 37455531 — intervention group
Group type: COMPARATOR
Intervention: Patients without depressive symptoms in CAD
Number of subjects: 587
Study 37455531 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with depressive symptoms in DM
Number of subjects: 587
Study 37455531 — intervention group
Group type: COMPARATOR
Intervention: Patients without depressive symptoms in DM
Number of subjects: 587
Study 37455588 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritlecitinib 30 mg and higher
Number of subjects: 105
Study 37455588 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 37455644 — intervention group
Group type: COMPARATOR
Intervention: Group 40 (maintained at 40±5 mmHg CO2)
Number of subjects: 297
Study 37455644 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 50 (maintained at 50±5 mmHg CO2)
Number of subjects: 297
Study 37455644 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 60 (maintained at 60±5 mmHg CO2)
Number of subjects: 297
Study 37456251 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D conformational RT
Number of subjects: 1565
Study 37456251 — intervention group
Group type: EXPERIMENTAL
Intervention: V30 Gy >15%
Number of subjects: 1565
Study 37456251 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary medical history
Number of subjects: 1565
Study 37456251 — intervention group
Group type: EXPERIMENTAL
Intervention: High V30 Gy
Number of subjects: 1565
Study 37456281 — intervention group
Group type: EXPERIMENTAL
Intervention: MRgFUS thalamotomy
Number of subjects: 9
Study 37456358 — intervention group
Group type: EXPERIMENTAL
Intervention: Carrying genetic variants of OPRM1 (rs1799971, A>G)
Number of subjects: 102
Study 37456358 — intervention group
Group type: EXPERIMENTAL
Intervention: Carrying genetic variants of ABCB1
Number of subjects: 102
Study 37456358 — intervention group
Group type: EXPERIMENTAL
Intervention: Carrying genetic variant rs2952768
Number of subjects: 102
Study 37456507 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate (bisphosphonate), administered monthly for six months
Number of subjects: 120
Study 37456507 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 37456641 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted multidomain (T-MD) intervention
Number of subjects: 250
Study 37456641 — intervention group
Group type: COMPARATOR
Intervention: Usual care (behavioral management)
Number of subjects: 250
Study 37456676 — intervention group
Group type: EXPERIMENTAL
Intervention: Odevixibat 120 μg/kg per day
Number of subjects: 69
Study 37456802 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermocosmetic (DC) applied twice a day for 28 days
Number of subjects: 107
Study 37456802 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermocosmetic (DC)
Number of subjects: 107
Study 37456813 — intervention group
Group type: EXPERIMENTAL
Intervention: PRIORITY intervention (hybrid centre and home-based personalized exercise and physical activity intervention)
Number of subjects: 312
Study 37456813 — intervention group
Group type: COMPARATOR
Intervention: Written exercise prescription (control group)
Number of subjects: 312
Study 37456818 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal prehabilitation program (nutrition guidance, diet journal, mindfulness training, exercise guidance)
Number of subjects: 152
Study 37456818 — intervention group
Group type: COMPARATOR
Intervention: Standard care (patient education, counseling, personal guidance on exercise, breathing, and coughing)
Number of subjects: 152
Study 37457284 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle factors (diet, physical activity, tobacco, and alcohol)
Number of subjects: 1000
Study 37457284 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbiome
Number of subjects: 1000
Study 37457622 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine (0.5 mg tablet) given twice daily starting 2 to 4 hours before surgery for a total of 10 days
Number of subjects: 3200
Study 37457622 — intervention group
Group type: COMPARATOR
Intervention: Placebo, given twice daily starting 2 to 4 hours before surgery for a total of 10 days
Number of subjects: 3200
Study 37457966 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated SARS-CoV-2 vaccine
Number of subjects: 115
Study 37457966 — intervention group
Group type: COMPARATOR
Intervention: CHB adults (control group)
Number of subjects: 115
Study 37458272 — intervention group
Group type: EXPERIMENTAL
Intervention: Solanezumab
Number of subjects: 1169
Study 37458272 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1169
Study 37458369 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublay biologic mesh
Number of subjects: 107
Study 37458369 — intervention group
Group type: COMPARATOR
Intervention: No mesh
Number of subjects: 107
Study 37458369 — intervention group
Group type: EXPERIMENTAL
Intervention: Small bites (0.5 × 0.5cm)
Number of subjects: 107
Study 37458369 — intervention group
Group type: COMPARATOR
Intervention: Large bites (1 × 1 cm)
Number of subjects: 107
Study 37458583 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF+pegIFN+NAPs (early triple therapy group)
Number of subjects: 40
Study 37458583 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF+pegIFN (delayed triple therapy group)
Number of subjects: 40
Study 37458583 — intervention group
Group type: EXPERIMENTAL
Intervention: Monophasic HBsAg decline
Number of subjects: 40
Study 37458583 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonmonophasic HBsAg kinetic pattern
Number of subjects: 40
Study 37458698 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TOMAC
Number of subjects: 133
Study 37458698 — intervention group
Group type: COMPARATOR
Intervention: Sham TOMAC
Number of subjects: 133
Study 37458805 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal recombinant human ASA
Number of subjects: 12
Study 37459054 — intervention group
Group type: EXPERIMENTAL
Intervention: Trainee-performed intestinal ultrasound (IUS)
Number of subjects: 129
Study 37459054 — intervention group
Group type: COMPARATOR
Intervention: Magnetic resonance enterocolonography (MREC)
Number of subjects: 129
Study 37459059 — intervention group
Group type: EXPERIMENTAL
Intervention: Screen and treat for BV using self-collected vaginal swabs (n=3333)
Number of subjects: 6671
Study 37459059 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n=3338)
Number of subjects: 6671
Study 37459059 — intervention group
Group type: EXPERIMENTAL
Intervention: Screen and treat for BV in nulliparous women (n=3438)
Number of subjects: 6671
Study 37459059 — intervention group
Group type: COMPARATOR
Intervention: Usual care in multiparous women
Number of subjects: 6671
Study 37459059 — intervention group
Group type: EXPERIMENTAL
Intervention: Screen and treat for BV
Number of subjects: 6671
Study 37459059 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 6671
Study 37459086 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct oral challenge with penicillin
Number of subjects: 377
Study 37459086 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care: penicillin skin testing followed by oral challenge
Number of subjects: 377
Study 37459089 — intervention group
Group type: EXPERIMENTAL
Intervention: Gun safety video
Number of subjects: 226
Study 37459089 — intervention group
Group type: COMPARATOR
Intervention: Car safety video
Number of subjects: 226
Study 37459141 — intervention group
Group type: EXPERIMENTAL
Intervention: Donanemab (n=860)
Number of subjects: 1736
Study 37459141 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=876)
Number of subjects: 1736
Study 37459153 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose intravenous magnesium sulfate (IVMg)
Number of subjects: 90
Study 37459153 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous magnesium sulfate (IVMg)
Number of subjects: 90
Study 37459153 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 37459153 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (IVMg and placebo)
Number of subjects: 90
Study 37459203 — intervention group
Group type: EXPERIMENTAL
Intervention: sutimlimab
Number of subjects: 22
Study 37459248 — intervention group
Group type: EXPERIMENTAL
Intervention: Obexelimab 5 mg/kg intravenously every 2 weeks until week 32 or loss of improvement (LOI)
Number of subjects: 104
Study 37459248 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 37459248 — intervention group
Group type: EXPERIMENTAL
Intervention: Obexelimab
Number of subjects: 104
Study 37459306 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Health Partners (FGP)
Number of subjects: 102
Study 37459306 — intervention group
Group type: COMPARATOR
Intervention: Control group (no FGP intervention)
Number of subjects: 102
Study 37459335 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol
Number of subjects: 51
Study 37459335 — intervention group
Group type: EXPERIMENTAL
Intervention: Methacholine
Number of subjects: 51
Study 37459335 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 37459873 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab plus vemurafenib and cobimetinib
Number of subjects: 65
Study 37460024 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous immunotherapy (SCIT)
Number of subjects: 84
Study 37460024 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 84
Study 37460024 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 37460214 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy (MT)
Number of subjects: 13082
Study 37460214 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher pre-stroke disability (mRS 3-5)
Number of subjects: 13082
Study 37460214 — intervention group
Group type: EXPERIMENTAL
Intervention: Absence of bridging intravenous thrombolysis
Number of subjects: 13082
Study 37460214 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer time to treatment
Number of subjects: 13082
Study 37460214 — intervention group
Group type: EXPERIMENTAL
Intervention: High post-stroke disability at discharge (mRS 3-5)
Number of subjects: 13082
Study 37460214 — intervention group
Group type: EXPERIMENTAL
Intervention: Futile recanalization (TICI score of 0-2a)
Number of subjects: 13082
Study 37460214 — intervention group
Group type: EXPERIMENTAL
Intervention: Shorter hospital stay
Number of subjects: 13082
Study 37460214 — intervention group
Group type: EXPERIMENTAL
Intervention: Discharge to institutional care or hospital
Number of subjects: 13082
Study 37460257 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated blood test measuring serum GFAP and UCH-L1 within 12 hours after mTBI
Number of subjects: 2370
Study 37460257 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated blood test measuring serum GFAP and UCH-L1
Number of subjects: 2370
Study 37460257 — intervention group
Group type: COMPARATOR
Intervention: Reference values for GFAP and UCH-L1
Number of subjects: 2370